Cells (Aug 2023)

A Protocol for Organoids from the Urine of Bladder Cancer Patients

  • Simon Walz,
  • Paul Pollehne,
  • Ruizhi Geng,
  • Johannes Schneider,
  • Moritz Maas,
  • Wilhelm K. Aicher,
  • Arnulf Stenzl,
  • Bastian Amend,
  • Niklas Harland

DOI
https://doi.org/10.3390/cells12172188
Journal volume & issue
Vol. 12, no. 17
p. 2188

Abstract

Read online

This study investigates the feasibility of establishing urine-derived tumor organoids from bladder cancer (BC) patients as an alternative to tissue-derived organoids. BC is one of the most common cancers worldwide and current diagnostic methods involve invasive procedures. Here, we investigated the potential of using urine samples, which contain exfoliated tumor cells, to generate urine-derived BC organoids (uBCOs). Urine samples from 29 BC patients were collected and cells were isolated and cultured in a three-dimensional matrix. The establishment and primary expansion of uBCOs were successful in 83% of the specimens investigated. The culturing efficiency of uBCOs was comparable to cancer tissue-derived organoids. Immunohistochemistry and immunofluorescence to characterize the uBCOs exhibited similar expressions of BC markers compared to the parental tumor. These findings suggest that urine-derived BC organoids hold promise as a non-invasive tool for studying BC and evaluating therapeutic responses. This approach could potentially minimize the need for invasive procedures and provide a platform for personalized drug screening. Further research in this area may lead to improved diagnostic and treatment strategies for BC patients.

Keywords